SEC Form DEFA14A filed by Viatris Inc.

$VTRS
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $VTRS alert in real time by email
DEFA14A 1 d816790ddefa14a.htm DEFA14A DEFA14A

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934

(Amendment No.  )

 

 

Filed by the Registrant ☒        Filed by a party other than the Registrant ☐

Check the appropriate box:

 

  Preliminary Proxy Statement
  Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
  Definitive Proxy Statement
  Definitive Additional Materials
  Soliciting Material under §240.14a-12

VIATRIS INC.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check all boxes that apply):

 

  No fee required.
  Fee paid previously with preliminary materials.
  Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

 

 

 


LOGO

Important Notice Regarding the Availability of Proxy Materials for the

Viatris Inc. (the “Company”) Annual Meeting of Shareholders To Be Held on December 6, 2024

Under U.S. Securities and Exchange Commission rules, you are receiving this notice that the proxy materials for our 2024 annual meeting of shareholders (the “2024 Annual Meeting”) are available on the Internet. Follow the instructions below to view the proxy materials and to submit your proxy and voting instructions online. The items to be voted on and location of the 2024 Annual Meeting are on the reverse side of this notice. Your vote is important!

This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before submitting your proxy and voting instructions.

To view the proxy materials, which consist of the Proxy Statement and 2023 Annual Report, request a paper or email copy of the proxy materials, and/or select a future delivery preference, please have this notice available and visit www.eproxyaccess.com/vtrs2024. You will be required to use the control number located in the shaded box below.

 

LOGO

After you have reviewed the proxy materials, you may submit your proxy and voting instructions over the Internet at:

https://www.proxyvotenow.com/vtrs

Please have this notice available when you access the voting website. You will be required to use your control number located in the shaded box above to log in and vote. Please note that submitting your proxy and voting instructions online authorizes the named proxies to vote your shares in the same manner as if you marked, signed and returned a proxy card.

If you would like to receive a paper or email copy of the proxy materials and/or select a future delivery preference, you must do so using one of the following options:

 

LOGO

   Internet – Go to www.eproxyaccess.com/vtrs2024 and follow the registration instructions.

LOGO

   Telephone – Call us free of charge at 1-855-708-9771 from within the United States or Canada.

LOGO

   E-mail – Send us an e-mail at vtrs@eproxyaccess.com, using the control number above as the subject line, and state whether you wish to receive a paper or e-mail copy of the proxy materials and whether your request is for this meeting only or for all future meetings.

If you want to receive a paper or e-mail copy of the proxy materials, you must request one. There is no charge to you for requesting a copy. Please make your request for a copy as instructed above on or before November 29, 2024 to facilitate timely delivery.


The 2024 Annual Meeting will be held on Friday, December 6, 2024

at 11 a.m. Eastern Time at the DoubleTree Crystal City.

The proposals to be voted on at the 2024 Annual Meeting are listed below along with Viatris’ Board of Directors’ (the “Board of Directors”) recommendations.

THE VIATRIS INC. BOARD OF DIRECTORS RECOMMENDS A VOTE “FOR” EACH DIRECTOR IN ITEM 1 AND “FOR” ITEMS 2, 3 AND 4.

 

  1.

Election of the following 12 directors, each to hold office until the 2025 annual meeting of shareholders:

 

A. W. Don Cornwell

 

E. Melina Higgins

 

I. Richard Mark

B. JoEllen Lyons Dillon

 

F. James M. Kilts

 

J. Mark Parrish

C. Elisha Finney

 

G. Harry Korman

 

K. Scott A. Smith

D. Leo Groothuis

 

H. Rajiv Malik

  L. Rogério Vivaldi Coelho

 

  2.

Approval of, on a non-binding advisory basis, the 2023 compensation of the named executive officers of the Company.

 

  3.

Ratification of the selection of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024.

 

  4.

Approval of an amendment to the Viatris Inc. 2020 Stock Incentive Plan.

After you have reviewed the proxy materials, you may submit your proxy and voting instructions online at https://www.proxyvotenow.com/vtrs by logging in with your control number located in the shaded box on the front of this notice.

You are entitled to vote at the 2024 Annual Meeting only if you were a shareholder of Viatris Inc. as of the close of business (5:00 p.m. Eastern Time) on October 11, 2024, which is the record date for the 2024 Annual Meeting.

PLEASE NOTE – YOU CANNOT VOTE BY RETURNING THIS NOTICE. To vote your shares of Viatris Inc. common stock you must submit your proxy and voting instructions online or request a paper or email copy of the proxy materials to receive a proxy card. Please also note that if you plan to attend the 2024 Annual Meeting, you must register in advance and provide proper identification and this notice. See the question titled “How can I attend the 2024 Annual Meeting?” on page A-2 of the Proxy Statement for information about the location, format and how to register to attend the meeting.

Directions to the 2024 Annual Meeting: If you plan to attend our 2024 Annual Meeting in person, you can obtain directions to DoubleTree Crystal City (300 Army Navy Drive, Arlington, VA 22202) at the hotel’s website, https://www.hilton.com/en/hotels/dcaaedt-doubletree-washington-dc-crystal-city/hotel-location/.

Get the next $VTRS alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$VTRS

DatePrice TargetRatingAnalyst
7/19/2024$15.00Buy
Jefferies
10/23/2023$13.00 → $9.00Neutral → Underperform
BofA Securities
6/23/2023$11.00Equal Weight → Underweight
Barclays
4/24/2023$11.00Overweight → Equal Weight
Barclays
2/17/2023$16.00 → $14.00Outperform → Market Perform
BMO Capital Markets
1/27/2023$13.00 → $15.00Hold → Buy
Jefferies
11/10/2022$9.00 → $12.00Sell → Neutral
UBS
11/8/2022$10.00Underweight → Neutral
Piper Sandler
More analyst ratings

$VTRS
Press Releases

Fastest customizable press release news feed in the world

See more
  • Viatris to Report First Quarter 2025 Financial Results on May 8, 2025

    PITTSBURGH, March 28, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) will report first quarter 2025 financial results on Thursday, May 8, 2025. Company executives will host a webcast at 8:30 a.m. ET on the same date to discuss the results. Investors and the general public are invited to listen to a live webcast of the call at investor.viatris.com or by calling 844.308.3344 or 412.317.1896 for international callers. A replay of the webcast also will be available on the website. About Viatris Viatris Inc. (NASDAQ:VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthc

    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Viatris to Present at the Barclays 27th Annual Global Healthcare Conference

    PITTSBURGH, March 5, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a global healthcare company, will present at the Barclays 27th Annual Global Healthcare Conference in Miami Beach, FL on Tuesday, March 11, 2025. The company's fireside chat will begin at 2 p.m. ET. A live webcast of the event at can be found at investor.viatris.com. An archived version of the presentation will be available following the live event and can be accessed at the same location for a limited time. About ViatrisViatris Inc. (NASDAQ:VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcar

    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Nxera Pharma Assigns Japan and APAC (ex-China) Rights to Cenerimod for Autoimmune Diseases to Viatris

    Cenerimod is a novel oral S1P1 receptor modulator with potential to be a first- or best-in-class therapy for multiple autoimmune diseasesViatris previously acquired rights to cenerimod in all other territories from Idorsia, and now has exclusive global rightsNxera will receive an upfront payment of US$10 million from Viatris, and is eligible to receive a further milestone payment upon regulatory approval of cenerimod in Japan plus royalties on net sales in the assigned territories Tokyo, Japan and Cambridge, UK, 28 February 2025 – Nxera Pharma ("the Company" or "Nxera"; TSE: 4565) has entered an assignment agreement with Viatris Inc. ("Viatris"), a global healthcare company, and Idorsia Pha

    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

$VTRS
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$VTRS
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$VTRS
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$VTRS
SEC Filings

See more

$VTRS
Leadership Updates

Live Leadership Updates

See more
  • Viatris Appoints Rogerio Vivaldi Coelho, M.D., to Board of Directors

    PITTSBURGH, June 3, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced that as part of its ongoing Board refreshment efforts, Rogerio Vivaldi Coelho, M.D., has been appointed as the newest member of its Board of Directors. Dr. Vivaldi will serve as a member of the recently reestablished Science and Technology Committee of the Board of Directors. "We are pleased to welcome Dr. Vivaldi to our Board of Directors," said Melina Higgins, Chair of the Board, Viatris. "We believe his proven expertise and long track record of success will enhance the efforts of the Board across a range of areas, in particular with regards to our Science and Technology Commit

    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Viatris Appoints Corinne Le Goff as Chief Commercial Officer

    PITTSBURGH, April 15, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced that Corinne Le Goff has joined the company as Chief Commercial Officer and will become a member of the company's Executive Leadership Team, effective today. Le Goff is an accomplished biotechnology and pharmaceutical executive with more than 25 years of experience leading and building highly successful teams globally. She is a visionary and entrepreneurial leader with a strong scientific background and experience across multiple markets and therapeutic areas. Prior to joining Viatris, Le Goff was President and Chief Executive Officer of Imunon, a clinical-stage biotechnology

    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Viatris Continues its Preparations for Phase 2 of its Strategic Plan by Announcing the Appointment of Theodora "Doretta" Mistras as Chief Financial Officer, Effective March 1, 2024, and Philippe Martin as Chief R&D Officer

    Company thanks Sanjeev Narula for his role in the successful execution of Viatris' Phase 1 strategy; Narula will support a smooth CFO transition prior to his departure on March 1, 2024 PITTSBURGH, Dec. 15, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced that, as it prepares to enter Phase 2 of its strategic plan, Theodora "Doretta" Mistras has been appointed Chief Financial Officer (CFO) effective March 1, 2024, and Philippe Martin has been appointed Chief R&D Officer with immediate effect. Current Viatris CFO Sanjeev Narula, who h

    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

$VTRS
Financials

Live finance-specific insights

See more
  • Viatris to Report First Quarter 2025 Financial Results on May 8, 2025

    PITTSBURGH, March 28, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) will report first quarter 2025 financial results on Thursday, May 8, 2025. Company executives will host a webcast at 8:30 a.m. ET on the same date to discuss the results. Investors and the general public are invited to listen to a live webcast of the call at investor.viatris.com or by calling 844.308.3344 or 412.317.1896 for international callers. A replay of the webcast also will be available on the website. About Viatris Viatris Inc. (NASDAQ:VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthc

    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Viatris Reports Fourth Quarter and Full Year 2024 Financial Results and Provides 2025 Financial Guidance

    PITTSBURGH, Feb. 27, 2025 /PRNewswire/ --  Meets 2024 Guidance for Total Revenues, Adjusted EBITDA and Adjusted EPS; Exceeds 2024 Guidance for Free Cash Flow [1]Reports 2024 Total Revenues of $14.7 Billion, U.S. GAAP Net Loss of $(634) Million, Adjusted EBITDA of $4.7 Billion, U.S. GAAP Diluted EPS Loss of $(0.53) per Share, Adjusted EPS of $2.65 per Share, U.S. GAAP Net Cash Provided by Operating Activities of $2.3 Billion, and Free Cash Flow of $2.0 Billion Including ~$650 Million of Transaction-Related CostsDelivers Strong New Product Revenues of $582 Million in 2024Returns $825 Million in Capital to Shareholders and Repays $3.7 Billion of Debt in 2024An

    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Viatris Maintains Dividend Policy for 2025 and Announces Quarterly Dividend

    PITTSBURGH, Feb. 27, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) today announced that on February 24, 2025, its Board of Directors approved a 2025 dividend policy of 48 cents ($0.48) per share and declared a quarterly dividend of 12 cents ($0.12) for each issued and outstanding share of the Company's common stock. The dividend is payable on March 18, 2025, to shareholders of record at the close of business on March 10, 2025. This marks the fifth consecutive year the Company has paid a dividend. About ViatrisViatris Inc. (NASDAQ:VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistic

    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

$VTRS
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more